Endocrinology, Vol 122, 1146-1150, Copyright © 1988 by Endocrine Society

ARTICLES

Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats

RT Turner, GK Wakley, KS Hannon and NH Bell
Department of Physiology, Loma Linda University, Pettis Veterans Administration Hospital, California 92354.

The effects of the nonsteroidal antiestrogen tamoxifen were determined on trabecular bone mass in the proximal tibial metaphysis of intact and ovariectomized rats. Rats were ovariectomized at the beginning of the study. On day 7 of the study, 5-mg slow release pellets of tamoxifen or placebo were implanted sc. All of the rats were killed on day 28 of the experiment. Sections of the proximal tibial metaphysis were stained for acid phosphatase and evaluated histomorphometrically. Ovariectomy resulted in marked loss of bone. Compared to the values in sham- operated animals, the trabecular bone at a sampling site in the secondary spongiosa of ovariectomized rats was reduced by more than 60%, the length of trabecular bone surface covered by osteoclasts was increased by 563%, the percentage of trabecular bone surface covered by osteoclasts was increased by 567%, the mean osteoclast size was increased by 84%, and the number of nuclei per osteoclast was increased by 38%. In contrast, treatment of ovariectomized rats for 3 weeks with tamoxifen restored the histomorphometric measurements to values comparable to those in sham-operated animals. 17 beta-Estradiol increased trabecular bone fractional area in ovariectomized and sham- operated rats, and administration of tamoxifen to estrogen-treated, ovariectomized, and sham-operated animals produced a further increase in trabecular bone. In summary, 1) ovariectomy resulted in large increases in both the number and activity of osteoclasts, 2) the increased bone resorption associated with ovariectomy produced a net loss of trabecular bone, and 3) treatment of ovariectomized rats with tamoxifen prevented these skeletal changes. The results indicate that in the rat, tamoxifen mimics the effects of estrogen on trabecular bone at concentrations that are not uterotropic.

This article has been cited by other articles:

				V. C. Jordan SERMs: Meeting the Promise of Multifunctional Medicines J Natl Cancer Inst, March 7, 2007; 99(5): 350 - 356. [Abstract] [Full Text] [PDF]

				M. J. Perry, S. Gujra, T. Whitworth, and J. H. Tobias Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice Endocrinology, March 1, 2005; 146(3): 1060 - 1065. [Abstract] [Full Text] [PDF]

				J. E. Aldridge, J. A. Gibbons, M. M. Flaherty, M. L. Kreider, J. A. Romano, and E. D. Levin Heterogeneity of Toxicant Response: Sources of Human Variability Toxicol. Sci., November 1, 2003; 76(1): 3 - 20. [Abstract] [Full Text] [PDF]

				E. V. Jensen and V. C. Jordan The Estrogen Receptor: A Model for Molecular Medicine Clin. Cancer Res., June 1, 2003; 9(6): 1980 - 1989. [Abstract] [Full Text] [PDF]

				B. L. Riggs and L. C. Hartmann Selective Estrogen-Receptor Modulators -- Mechanisms of Action and Application to Clinical Practice N. Engl. J. Med., February 13, 2003; 348(7): 618 - 629. [Full Text] [PDF]

				B. H. Arjmandi The Role of Phytoestrogens in the Prevention and Treatment of Osteoporosis in Ovarian Hormone Deficiency J. Am. Coll. Nutr., October 1, 2001; 20(90005): 398S - 402. [Abstract] [Full Text]

				V. C. Jordan Selective Estrogen Receptor Modulation: A Personal Perspective Cancer Res., August 1, 2001; 61(15): 5683 - 5687. [Full Text] [PDF]

				Y. Chen, M. Schindler, and S. M. Simon A Mechanism for Tamoxifen-mediated Inhibition of Acidification J. Biol. Chem., June 25, 1999; 274(26): 18364 - 18373. [Abstract] [Full Text] [PDF]

				M. Sato, G. Q. Zeng, E. Rowley, and C. H. Turner LY353381{middle dot}HCl: An Improved Benzothiophene Analog with Bone Efficacy Complementary to Parathyroid Hormone-(1-34) Endocrinology, November 1, 1998; 139(11): 4642 - 4651. [Abstract] [Full Text] [PDF]

				M. Sato, C. H. Turner, T. Wang, M. D. Adrian, E. Rowley, and H. U. Bryant LY353381.HCl: A Novel Raloxifene Analog with Improved SERM Potency and Efficacy In Vivo J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 1 - 7. [Abstract] [Full Text]

				J. I. Macgregor and V. C. Jordan Basic Guide to the Mechanisms of Antiestrogen Action Pharmacol. Rev., June 1, 1998; 50(2): 151 - 196. [Abstract] [Full Text] [PDF]

				H. Z. Ke, V. M. Paralkar, W. A. Grasser, D. T. Crawford, H. Qi, H. A. Simmons, C. M. Pirie, K. L. Chidsey-Frink, T. A. Owen, S. L. Smock, et al. Effects of CP-336,156, a New, Nonsteroidal Estrogen Agonist/Antagonist, on Bone, Serum Cholesterol, Uterus, and Body Composition in Rat Models Endocrinology, April 1, 1998; 139(4): 2068 - 2076. [Abstract] [Full Text] [PDF]

				P. J. Shughrue, M. V. Lane, and I. Merchenthaler Regulation of Progesterone Receptor Messenger Ribonucleic Acid in the Rat Medial Preoptic Nucleus by Estrogenic and Antiestrogenic Compounds: An in Situ Hybridization Study Endocrinology, December 1, 1997; 138(12): 5476 - 5484. [Abstract] [Full Text] [PDF]

				M. A. Jimenez, D. E. Magee, H. U. Bryant, and R. T. Turner Clomiphene Prevents Cancellous Bone Loss from Tibia of Ovariectomized Rats Endocrinology, May 1, 1997; 138(5): 1794 - 1800. [Abstract] [Full Text] [PDF]

				J. P. Williams, H. C. Blair, M. A. McKenna, S. E. Jordan, and J. M. McDonald Regulation of Avian Osteoclastic H[IMAGE]-ATPase and Bone Resorption by Tamoxifen and Calmodulin Antagonists J. Biol. Chem., May 24, 1996; 271(21): 12488 - 12495. [Abstract] [Full Text] [PDF]

				S. C. Manolagas and R. L. Jilka Bone Marrow, Cytokines, and Bone Remodeling -- Emerging Insights into the Pathophysiology of Osteoporosis N. Engl. J. Med., February 2, 1995; 332(5): 305 - 311. [Full Text] [PDF]

				R. Jilka, G Hangoc, G Girasole, G Passeri, D. Williams, J. Abrams, B Boyce, H Broxmeyer, and S. Manolagas Increased osteoclast development after estrogen loss: mediation by interleukin-6 Science, July 3, 1992; 257(5066): 88 - 91. [Abstract] [PDF]